Loading…
Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies
Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Fu...
Saved in:
Published in: | Cancers 2023-12, Vol.16 (1), p.126 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3 |
container_end_page | |
container_issue | 1 |
container_start_page | 126 |
container_title | Cancers |
container_volume | 16 |
creator | Tarpgaard, Line Schmidt Winther, Stine Brændegaard Pfeiffer, Per |
description | Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions). |
doi_str_mv | 10.3390/cancers16010126 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10777930</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A779132435</galeid><sourcerecordid>A779132435</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3</originalsourceid><addsrcrecordid>eNptkktv1TAQhSNERau2a3YoEhs2acePOAkbVF3RghSpUilr49jj4iqxL3ZSCX49Di19qfbCo_F3znisKYq3BI4Y6-BYK68xJiKAAKHiVbFHoaGVEB1__SjeLQ5Tuoa8GCONaN4Uu6ylQOqa7RU_LiOqeUI_l-fb2QWfSufLXs1Y9c5juQljiKhnNZabf-U-lj2mtHI9qujRlDaGqbxAvXpcKG_C5P7k9Ld5MQ7TQbFj1Zjw8O7cL76ffr7cfKn687Ovm5O-0pyzuSLWMEOZsgpsjd2gSQM4gGg7KgQ1xNCurZW1bUP0AJyKDlrVAoehVYyAYfvFp1vf7TJMaNbXRDXKbXSTir9lUE4-vfHup7wKN5JA0zQdg-zw4c4hhl8LpllOLmkcR-UxLEnSjjBeQ8tFRt8_Q6_DEn3ub6VozTsQ9IG6UiNK523IhfVqKk9yScIoZ3Wmjl6g8jY4OR08WpfzTwTHtwIdQ0oR7X2TBOQ6GPLZYGTFu8d_c8__HwP2F2wSs3k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912549062</pqid></control><display><type>article</type><title>Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central(OpenAccess)</source><creator>Tarpgaard, Line Schmidt ; Winther, Stine Brændegaard ; Pfeiffer, Per</creator><creatorcontrib>Tarpgaard, Line Schmidt ; Winther, Stine Brændegaard ; Pfeiffer, Per</creatorcontrib><description>Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16010126</identifier><identifier>PMID: 38201553</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Angiogenesis ; Antimitotic agents ; Antineoplastic agents ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; ErbB-2 protein ; FDA approval ; Gene mutations ; Genetic aspects ; Irinotecan ; Kinases ; Metastases ; Metastasis ; Monoclonal antibodies ; Mutation ; Oncology ; Oncology, Experimental ; Oxaliplatin ; Patients ; Quality of life ; Review ; Trifluridine ; Tumors</subject><ispartof>Cancers, 2023-12, Vol.16 (1), p.126</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3</cites><orcidid>0000-0002-2925-0586 ; 0000-0001-8505-2544</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2912549062/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2912549062?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38201553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tarpgaard, Line Schmidt</creatorcontrib><creatorcontrib>Winther, Stine Brændegaard</creatorcontrib><creatorcontrib>Pfeiffer, Per</creatorcontrib><title>Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).</description><subject>Angiogenesis</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>ErbB-2 protein</subject><subject>FDA approval</subject><subject>Gene mutations</subject><subject>Genetic aspects</subject><subject>Irinotecan</subject><subject>Kinases</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Oxaliplatin</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Review</subject><subject>Trifluridine</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkktv1TAQhSNERau2a3YoEhs2acePOAkbVF3RghSpUilr49jj4iqxL3ZSCX49Di19qfbCo_F3znisKYq3BI4Y6-BYK68xJiKAAKHiVbFHoaGVEB1__SjeLQ5Tuoa8GCONaN4Uu6ylQOqa7RU_LiOqeUI_l-fb2QWfSufLXs1Y9c5juQljiKhnNZabf-U-lj2mtHI9qujRlDaGqbxAvXpcKG_C5P7k9Ld5MQ7TQbFj1Zjw8O7cL76ffr7cfKn687Ovm5O-0pyzuSLWMEOZsgpsjd2gSQM4gGg7KgQ1xNCurZW1bUP0AJyKDlrVAoehVYyAYfvFp1vf7TJMaNbXRDXKbXSTir9lUE4-vfHup7wKN5JA0zQdg-zw4c4hhl8LpllOLmkcR-UxLEnSjjBeQ8tFRt8_Q6_DEn3ub6VozTsQ9IG6UiNK523IhfVqKk9yScIoZ3Wmjl6g8jY4OR08WpfzTwTHtwIdQ0oR7X2TBOQ6GPLZYGTFu8d_c8__HwP2F2wSs3k</recordid><startdate>20231226</startdate><enddate>20231226</enddate><creator>Tarpgaard, Line Schmidt</creator><creator>Winther, Stine Brændegaard</creator><creator>Pfeiffer, Per</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2925-0586</orcidid><orcidid>https://orcid.org/0000-0001-8505-2544</orcidid></search><sort><creationdate>20231226</creationdate><title>Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies</title><author>Tarpgaard, Line Schmidt ; Winther, Stine Brændegaard ; Pfeiffer, Per</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Angiogenesis</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>ErbB-2 protein</topic><topic>FDA approval</topic><topic>Gene mutations</topic><topic>Genetic aspects</topic><topic>Irinotecan</topic><topic>Kinases</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Oxaliplatin</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Review</topic><topic>Trifluridine</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tarpgaard, Line Schmidt</creatorcontrib><creatorcontrib>Winther, Stine Brændegaard</creatorcontrib><creatorcontrib>Pfeiffer, Per</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tarpgaard, Line Schmidt</au><au>Winther, Stine Brændegaard</au><au>Pfeiffer, Per</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-12-26</date><risdate>2023</risdate><volume>16</volume><issue>1</issue><spage>126</spage><pages>126-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38201553</pmid><doi>10.3390/cancers16010126</doi><orcidid>https://orcid.org/0000-0002-2925-0586</orcidid><orcidid>https://orcid.org/0000-0001-8505-2544</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2023-12, Vol.16 (1), p.126 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10777930 |
source | Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central(OpenAccess) |
subjects | Angiogenesis Antimitotic agents Antineoplastic agents Cancer Cancer therapies Care and treatment Chemotherapy Clinical trials Colorectal cancer Colorectal carcinoma ErbB-2 protein FDA approval Gene mutations Genetic aspects Irinotecan Kinases Metastases Metastasis Monoclonal antibodies Mutation Oncology Oncology, Experimental Oxaliplatin Patients Quality of life Review Trifluridine Tumors |
title | Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A00%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20Options%20in%20Late-Line%20Colorectal%20Cancer:%20Lessons%20Learned%20from%20Recent%20Randomized%20Studies&rft.jtitle=Cancers&rft.au=Tarpgaard,%20Line%20Schmidt&rft.date=2023-12-26&rft.volume=16&rft.issue=1&rft.spage=126&rft.pages=126-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16010126&rft_dat=%3Cgale_pubme%3EA779132435%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2912549062&rft_id=info:pmid/38201553&rft_galeid=A779132435&rfr_iscdi=true |